MétaCan
Menu
← Back to cohort
Record W2898387476 · doi:10.1093/annonc/mdy297.007

Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval

2018· article· en· W2898387476 on OpenAlexaff
M. Borrell Puy, C. Moltó Valiente, Kerstin Noëlle Vokinger, Thomas J. Hwang, Arnoud J. Templeton, Boštjan Šeruga, Ignasi Gich Saladich, Agustí Barnadas, Eitan Amir, Ariadna Tibau

Bibliographic record

VenueAnnals of Oncology · 2018
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicPharmaceutical Economics and Policy
Canadian institutionsPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineClinical trialFood and drug administrationMarketing authorizationAuthorizationFamily medicineInternal medicinePharmacologyBioinformatics

Abstract

fetched live from OpenAlex

Background: AA and CMA regulations were established by the US FDA and EMA, respectively, to improve access to drugs for life-threatening diseases. Here, we evaluate the magnitude of clinical benefit as measured by European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in trials supporting AA and CMA and confirmatory trials supporting conversion to regular approval (RA).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.188
metaresearch head score (Gemma)0.246
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Evaluation · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.812
Threshold uncertainty score0.995

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1880.246
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.005
Bibliometrics0.0060.004
Science and technology studies0.0010.002
Scholarly communication0.0040.004
Open science0.0010.003
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.406
GPT teacher head0.484
Teacher spread0.078 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainEvaluation
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueAnnals of Oncology→Same topicPharmaceutical Economics and Policy→French-language works237,207→